Furthermore, this solves one of the key problems 23andMe has had with the FDA over notifying users. Specifically, that the FDA prohibited them from proactivite

Furthermore, this solves one of the key problems 23andMe has had with the FDA over notifying users. Specifically, that the FDA prohibited them from proactivitely notifying users about potentially dangerous mutations. Looks like they've gotten approval for a few breast cancer risk markers now, but that's well short of what they could do. If you're notifying users about a drug discovery program... the FDA can't gripe.